Clinical Trial

Open-label Extension Study in Participants With Early Alzheimer's Disease

Recruiting Phase 2

Summary

The study medicine GSK4527226 is being studied in participants with Alzheimer's Disease (AD) in study 219867 (the parent study, NCT06079190). This new study is an extension of that parent study called an open-label extension (OLE). An OLE is a clinical trial where all participants receive the same study medicine. Participants must already be in study 219867 to be able to take part in this study. This study will assess the long-term safety and efficacy of GSK4527226 in participants with early AD (including mild cognitive impairment \[MCI\] and mild dementia due to AD) who have completed the parent study.

Protocol Amendment History 3 amendments

This ClinicalTrials.gov record has been amended 3 times since 2025-08-01; most recent amendment 2026-01-30.

Status change: Not Yet Recruiting → Recruiting 2025-10-06

Trial Details

NCT Number	NCT07105709
Lead Sponsor	GlaxoSmithKline Collaborators: Alector Inc.
Conditions	Alzheimer's Disease
Enrollment	220 participants
Start Date	2025-08-14
Primary Completion	2028-09-15 (estimated)
Study Completion	2028-12-08 (estimated)
Updated on ClinicalTrials.gov	2026-02-02